Benzinga | May 21, 2021 08:31AM EDT

Lantheus Holdings Highlights Presentation Featuring F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting Jun. 4-8, 2021

Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company's Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021.

The presentation will be made available for the duration of conference.

Details for the ASCO presentation are as follows:

Session Title: Poster Session: Genitourinary Cancer -- Prostate, Testicular and Penile

Title: PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)--A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.

Presenter: Frederic Pouliot, M.D., Ph.D., F.R.C.S.C., Centre Hospitalier Universitaire (CHU) de Qu?bec-Universit? Laval

Abstract No: 5023